DexCom, Inc. (NASDAQ:DXCM) Shares Bought by SVB Wealth LLC

SVB Wealth LLC raised its holdings in DexCom, Inc. (NASDAQ:DXCM – Get Rating) by 8.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,501 shares of the medical device company’s stock after acquiring an additional 274 shares during the quarter. SVB Wealth LLC’s holdings in DexCom were worth $396,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of DXCM. Mirae Asset Global Investments Co. Ltd. lifted its holdings in DexCom by 31.9% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 270,999 shares of the medical device company’s stock valued at $138,643,000 after acquiring an additional 65,516 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in DexCom by 3,596.7% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,109 shares of the medical device company’s stock valued at $567,000 after buying an additional 1,079 shares in the last quarter. West Family Investments Inc. purchased a new stake in DexCom during the first quarter valued at about $209,000. Ergoteles LLC lifted its stake in DexCom by 60.6% during the first quarter. Ergoteles LLC now owns 1,681 shares of the medical device company’s stock valued at $860,000 after buying an additional 634 shares in the last quarter. Finally, Mackenzie Financial Corp lifted its stake in DexCom by 26.4% during the first quarter. Mackenzie Financial Corp now owns 29,516 shares of the medical device company’s stock valued at $15,100,000 after buying an additional 6,160 shares in the last quarter. 94.01% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DexCom

In related news, CEO Kevin R. Sayer sold 38,464 shares of the stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $109.94, for a total transaction of $4,228,732.16. Following the completion of the sale, the chief executive officer now directly owns 331,337 shares in the company, valued at approximately $36,427,189.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Kevin R. Sayer sold 38,464 shares of the stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $109.94, for a total transaction of $4,228,732.16. Following the completion of the sale, the chief executive officer now directly owns 331,337 shares in the company, valued at approximately $36,427,189.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 20,812 shares of the stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $114.46, for a total value of $2,382,141.52. Following the sale, the chief executive officer now owns 327,457 shares of the company’s stock, valued at $37,480,728.22. The disclosure for this sale can be found here. Insiders sold 141,835 shares of company stock worth $16,443,758 in the last ninety days. 0.41% of the stock is owned by company insiders.

DexCom Stock Performance

Shares of DexCom stock opened at $114.61 on Friday. The firm has a market capitalization of $44.43 billion, a P/E ratio of 163.73 and a beta of 1.16. The business’s fifty day simple moving average is $117.86 and its 200 day simple moving average is $114.51. The company has a current ratio of 2.02, a quick ratio of 1.82 and a debt-to-equity ratio of 0.54. DexCom, Inc. has a 12 month low of $67.11 and a 12 month high of $126.44.

DexCom (NASDAQ:DXCM – Get Rating) last posted its quarterly earnings data on Thursday, April 27th. The medical device company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.02. DexCom had a return on equity of 18.29% and a net margin of 9.68%. The firm had revenue of $7.45 billion during the quarter, compared to analysts’ expectations of $720.52 million. During the same period in the prior year, the business earned $0.08 EPS. The company’s revenue for the quarter was up 1085.0% compared to the same quarter last year. As a group, analysts anticipate that DexCom, Inc. will post 1.06 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Raymond James upped their price objective on shares of DexCom from $138.00 to $140.00 in a research note on Friday, April 28th. Barclays increased their price target on shares of DexCom from $110.00 to $115.00 in a research report on Monday, May 1st. UBS Group increased their price target on shares of DexCom from $142.00 to $150.00 in a research report on Friday, April 28th. StockNews.com started coverage on shares of DexCom in a research report on Thursday, May 18th. They issued a “buy” rating for the company. Finally, Stifel Nicolaus increased their price target on shares of DexCom from $130.00 to $140.00 in a research report on Friday, April 28th. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $126.81.

DexCom Profile

(Get Rating)

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.